Stock CMPS COMPASS PATHWAYS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company COMPASS Pathways plc

Equities

CMPS

US20451W1018

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 04:00:00 2024-05-13 pm EDT 		5-day change 1st Jan Change
8.12 USD +3.31% Intraday chart for COMPASS Pathways plc -5.69% -7.20%
May. 09 Transcript : COMPASS Pathways plc - Shareholder/Analyst Call
May. 08 Transcript : COMPASS Pathways plc, Q1 2024 Earnings Call, May 08, 2024

Business Summary

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Number of employees: 186

Managers

Managers TitleAgeSince
Kabir Kumar Nath CEO
 Chief Executive Officer 59 22-07-31
Greg Ryslik CTO
 Chief Tech/Sci/R&D Officer - -
Guy Goodwin CTO
 Chief Tech/Sci/R&D Officer 76 21-07-28
Stephen D. Schultz IRC
 Investor Relations Contact - 20-11-30
Mary-Rose Hughes PRN
 Corporate Officer/Principal - 20-04-30
Ben Harber SEC
 Corporate Secretary - -
Gary Gilmour PRN
 Corporate Officer/Principal - -
Matthew Owens LAW
 General Counsel 46 22-01-31
Anne Benedict HRO
 Human Resources Officer - 21-03-31
Trevor Anthony Mill PRN
 Corporate Officer/Principal 53 20-05-31

Members of the board

Members of the board TitleAgeSince
Linda McGoldrick BRD
 Director/Board Member 69 20-08-31
David Norton CHM
 Chairman 72 18-04-30
Robert McQuade BRD
 Director/Board Member 67 20-03-31
Daphne Karydas BRD
 Director/Board Member 49 23-09-17
Wayne Riley BRD
 Director/Board Member 64 21-03-31
Thomas Lönngren BRD
 Director/Board Member 73 19-08-31
Annalisa Jenkins BRD
 Director/Board Member 58 18-02-28
Kabir Kumar Nath CEO
 Chief Executive Officer 59 22-07-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 68,380,857 0 0 39.69 %
Stock B 1 45,760,250 45,302,648 ( 99.00 %) 0

Shareholders

NameEquities%Valuation
Millennium Management LLC
5.688 %
3,887,201 5.688 % 31 M $
TCG Crossover Management LLC
5.645 %
3,858,000 5.645 % 30 M $
Paradigm BioCapital Advisors LP
3.316 %
2,265,988 3.316 % 18 M $
ARK Investment Management LLC
3.162 %
2,161,234 3.162 % 17 M $
Vivo Capital LLC
2.353 %
1,608,000 2.353 % 13 M $
Citadel Advisors LLC (13f Subfiler)
2.290 %
1,565,000 2.290 % 12 M $
RA Capital Management LP
1.882 %
1,286,000 1.882 % 10 M $
Soleus Capital Management LP
1.411 %
964,550 1.411 % 8 M $
Aisling Capital Management LP
1.411 %
964,500 1.411 % 8 M $
Rosalind Advisors, Inc.
1.074 %
734,000 1.074 % 6 M $
NameEquities%Valuation
ATAI Life Sciences AG
26.26 %
9,435,758 26.26 % 74 M $
Ekaterina Malievskaia
22.32 %
8,018,534 22.32 % 63 M $
George Goldsmith
21.97 %
7,892,307 21.97 % 62 M $
Robert McQuade
4.438 %
1,594,677 4.438 % 13 M $
Thomas Lönngren
0.2478 %
89,049 0.2478 % 699 925 $
Teri Loxam
0.1746 %
62,718 0.1746 % 492 963 $
Annalisa Jenkins
0.0547 %
19,641 0.0547 % 154 378 $
David Norton
0.0525 %
18,873 0.0525 % 148 342 $
Kabir Kumar Nath
0.0274 %
9,848 0.0274 % 77 405 $
Matthew Owens
0.0112 %
4,040 0.0112 % 31 754 $

Company contact information

Compass Pathways Plc

33 Broadwick Street

WA14 2DT, London

+44 71 6676 6461

http://www.compasspathways.com
address COMPASS Pathways plc(CMPS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.12 USD
Average target price
41.25 USD
Spread / Average Target
+408.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
COMPASS PATHWAYS PLC Stock COMPASS Pathways plc
-7.20% 555M
MODERNA, INC. Stock Moderna, Inc.
+26.37% 48.16B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.01% 41.73B
LONZA GROUP AG Stock Lonza Group AG
+44.47% 41.03B
CELLTRION, INC. Stock Celltrion, Inc.
-5.31% 28.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.34% 25.59B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.69% 18.96B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+6.23% 12.92B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.99% 12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.38% 11.77B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CMPS Stock
  4. Company COMPASS Pathways plc
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW